Ransom Advisory Ltd Takes $98,000 Position in Becton, Dickinson and Company $BDX

Ransom Advisory Ltd acquired a new stake in Becton, Dickinson and Company (NYSE:BDX) in the 1st quarter, HoldingsChannel reports. The fund acquired 430 shares of the medical instruments supplier’s stock, valued at approximately $98,000.

Other large investors also recently made changes to their positions in the company. Saudi Central Bank acquired a new stake in shares of Becton, Dickinson and Company in the 1st quarter valued at approximately $26,000. Smallwood Wealth Investment Management LLC acquired a new stake in Becton, Dickinson and Company during the 1st quarter valued at $27,000. REAP Financial Group LLC lifted its holdings in Becton, Dickinson and Company by 75.3% during the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 55 shares during the last quarter. Alpine Bank Wealth Management acquired a new stake in Becton, Dickinson and Company during the 1st quarter valued at $29,000. Finally, Cornerstone Planning Group LLC lifted its holdings in Becton, Dickinson and Company by 341.4% during the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 99 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Michael David Garrison sold 1,185 shares of the firm’s stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the transaction, the executive vice president owned 4,887 shares in the company, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Claire Fraser sold 863 shares of the firm’s stock in a transaction on Friday, August 8th. The stock was sold at an average price of $192.30, for a total value of $165,954.90. Following the completion of the transaction, the director owned 23,143 shares in the company, valued at $4,450,398.90. The trade was a 3.59% decrease in their position. The disclosure for this sale can be found here. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Stock Down 1.0%

BDX opened at $188.57 on Thursday. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The company has a market capitalization of $54.05 billion, a P/E ratio of 33.91, a P/E/G ratio of 1.42 and a beta of 0.27. The stock has a fifty day moving average of $185.95 and a 200-day moving average of $192.31.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, topping analysts’ consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company had revenue of $5.51 billion for the quarter, compared to analysts’ expectations of $5.50 billion. During the same quarter last year, the business earned $3.50 earnings per share. Becton, Dickinson and Company’s revenue was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, equities analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be given a $1.04 dividend. The ex-dividend date is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 74.82%.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on BDX shares. Barclays cut their price target on Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating for the company in a report on Tuesday, June 3rd. Citigroup downgraded Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating and cut their price target for the company from $217.00 to $185.00 in a report on Thursday, May 22nd. Wells Fargo & Company raised their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a report on Friday, August 8th. Piper Sandler reaffirmed a “neutral” rating and set a $200.00 price target (up previously from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Finally, Morgan Stanley lifted their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Four investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $211.44.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.